BCL2 and neoplasm: Moreover, vandetanib treatment could decrease the protein expression of MCL‐1 and BCL‐2 and increase the expression of BAD, BAX and BAK in K562 tumor tissues (Fig. 5I), which was consistent with the regulation of apoptosis‐related proteins in cancer cells in vitro (Fig. 3B).